PT1026950E - Tratamento da esquizofrenia com ampaquinas e neurolepticos - Google Patents

Tratamento da esquizofrenia com ampaquinas e neurolepticos

Info

Publication number
PT1026950E
PT1026950E PT98957382T PT98957382T PT1026950E PT 1026950 E PT1026950 E PT 1026950E PT 98957382 T PT98957382 T PT 98957382T PT 98957382 T PT98957382 T PT 98957382T PT 1026950 E PT1026950 E PT 1026950E
Authority
PT
Portugal
Prior art keywords
schizophrenia
treatment
ampakins
neuroleptics
relates
Prior art date
Application number
PT98957382T
Other languages
English (en)
Inventor
Steven A Johnson
Gary A Rogers
Gary S Lynch
Original Assignee
Cortex Pharma Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22050462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1026950(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cortex Pharma Inc, Univ California filed Critical Cortex Pharma Inc
Publication of PT1026950E publication Critical patent/PT1026950E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT98957382T 1997-10-27 1998-10-26 Tratamento da esquizofrenia com ampaquinas e neurolepticos PT1026950E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6362797P 1997-10-27 1997-10-27

Publications (1)

Publication Number Publication Date
PT1026950E true PT1026950E (pt) 2006-06-30

Family

ID=22050462

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98957382T PT1026950E (pt) 1997-10-27 1998-10-26 Tratamento da esquizofrenia com ampaquinas e neurolepticos

Country Status (15)

Country Link
US (1) US6166008A (pt)
EP (1) EP1026950B1 (pt)
JP (1) JP2001520978A (pt)
CN (1) CN1281335A (pt)
AT (1) ATE317226T1 (pt)
AU (1) AU745641B2 (pt)
BR (1) BR9814106A (pt)
CA (1) CA2306817A1 (pt)
CY (1) CY1105557T1 (pt)
DE (1) DE69833451T2 (pt)
DK (1) DK1026950T3 (pt)
ES (1) ES2258825T3 (pt)
HK (1) HK1030338A1 (pt)
PT (1) PT1026950E (pt)
WO (1) WO1999021422A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450801C (en) 1992-07-24 2009-11-17 The Regent Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040229898A1 (en) * 2001-05-25 2004-11-18 The Regents Of The University Of California Cyclic bis-compounds clearing malformed proteins
JP2004538323A (ja) * 2001-08-10 2004-12-24 ザ ロックフェラー ユニバーシティー Ｄａｒｐｐ−３２リン酸化のモジュレーションのための組成物及び方法
US20060276462A1 (en) * 2003-01-13 2006-12-07 Deadwyler Sam A Method of treating cognitive decline due to sleep deprivation and stress
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
JP2007504136A (ja) 2003-08-28 2007-03-01 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
JP2007519733A (ja) * 2004-01-26 2007-07-19 コーテックス ファーマシューティカルズ インコーポレーティッド アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
EP2453024B1 (en) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2006034196A1 (en) * 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
EP1809104A4 (en) * 2004-09-23 2009-04-29 Alexander Michalow METHODS FOR REGULATING NEUROTRANSMITTER SYSTEMS BY INDUCING COUNTER-ADAPTATIONS
EP1855688A4 (en) * 2005-02-24 2011-09-14 Nicox Sa NON-STAINED OXIDE DIURETIC COMPOUNDS, COMPOSITIONS AND USE PROCESSES
TWI378090B (en) 2005-04-13 2012-12-01 Astex Therapeutics Ltd Pharmaceutical compounds
KR20060119373A (ko) * 2005-05-20 2006-11-24 엘지전자 주식회사 컴퓨터 시스템과 시스템 소프트웨어 설치방법 및 휴대용컴퓨터의 소프트웨어 설치방법
US20090019557A1 (en) 2005-11-12 2009-01-15 Huda Akil Fgf2-related methods for diagnosing and treating depression
US20090286797A1 (en) * 2005-11-22 2009-11-19 Dan Peters Novel Quinoxaline Derivatives and Their Medical Use
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US20080176793A1 (en) * 2006-09-18 2008-07-24 The Regents Of The University Of California Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
JP5721949B2 (ja) 2006-10-12 2015-05-20 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 複合薬剤
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044027A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical compounds having hsp90 inhibitory or modulating activity
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
US8198305B2 (en) * 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US20090006902A1 (en) * 2007-06-29 2009-01-01 International Business Machines Corporation Methods, systems, and computer program products for reporting fru failures in storage device enclosures
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8263591B2 (en) 2007-08-10 2012-09-11 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2010087980A2 (en) * 2009-02-02 2010-08-05 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for the treatment of respiratory depression
PT105083A (pt) 2009-04-28 2011-07-25 Univ De Coimbra Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US9700596B2 (en) 2011-03-04 2017-07-11 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
ES2673872T3 (es) 2012-06-05 2018-06-26 The Board Of Trustees Of The Leland Stanford Junior University Mimético del péptido NCAM para su uso en el tratamiento de trastorno de depresión mayor
UA127357C2 (uk) 2018-04-18 2023-07-26 Констеллатіон Фармацеутікалс, Інк. Модулятори метилмодифікуючих ферментів, композиції та їх використання
CA3100977A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
US5447948A (en) * 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
GB9507230D0 (en) * 1995-04-07 1995-05-31 Inst Of Psychiatry Novel method
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
DE69833451D1 (de) 2006-04-20
DE69833451T2 (de) 2006-09-28
HK1030338A1 (en) 2001-05-04
CN1281335A (zh) 2001-01-24
CA2306817A1 (en) 1999-05-06
ATE317226T1 (de) 2006-02-15
WO1999021422A1 (en) 1999-05-06
EP1026950A4 (en) 2004-07-07
US6166008A (en) 2000-12-26
DK1026950T3 (da) 2006-06-26
EP1026950B1 (en) 2006-02-08
BR9814106A (pt) 2000-10-03
AU1365899A (en) 1999-05-17
ES2258825T3 (es) 2006-09-01
EP1026950A1 (en) 2000-08-16
AU745641B2 (en) 2002-03-28
CY1105557T1 (el) 2010-07-28
JP2001520978A (ja) 2001-11-06

Similar Documents

Publication Publication Date Title
PT1026950E (pt) Tratamento da esquizofrenia com ampaquinas e neurolepticos
CY1115759T1 (el) Αντιβιοτικες συνθεσεις για θεραπεια του οφθαλμου
NO306779B1 (no) Naftalamider, anvendelse derav og farmasöytisk preparat
DE69429524D1 (de) Aminocyclohexylester und ihre anwendung
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
AU2002343557A1 (en) Substituted aryl 1,4-pyrazine derivatives
DE60024588D1 (de) Substituierte porphyrine und deren therapeutische verwendungen
DK0876818T3 (da) Middel til behnadling af nerodegenerative lidelser
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
PA8478501A1 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
DE69724811D1 (de) Pentafluorobenzensulfonamide und analoge
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
DE60025639D1 (de) Substituierte diazepan
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
TR199901385T2 (xx) Piperidin t�revleri.
TR200000916T2 (tr) İkameli piperidin türevleri.
BR9801346A (pt) Ligações aminoácidas substituìdas, processo para a geração de uma ligação aminoácida substituìda e aplicação de ligações aminoácidas substiuìdas